{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:55:59Z","timestamp":1692042959216},"reference-count":19,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10459","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T09:50:38Z","timestamp":1626429038000},"source":"Crossref","is-referenced-by-count":2,"title":["Musculoskeletal adverse reactions after immunotherapy for cancer: A case series"],"prefix":"10.3892","volume":"22","author":[{"given":"Ioana","family":"Cre\u0163u","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Bojinc\u0103","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Milicescu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Cursaru","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"\u0218erban","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Cre\u021bu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiu","family":"Iordache","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Pop","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103t\u0103lin","family":"C\u00eerstoiu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxandra","family":"Ionescu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"key20210812133133_b1-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.rdc.2016.09.007","article-title":"Immune-related adverse effects of cancer immunotherapy-Implications for rheumatology","volume":"43","author":"Cappeli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"key20210812133133_b2-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab inadvanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Eng J Med"},{"key":"key20210812133133_b3-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestation among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"key20210812133133_b4-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"key20210812133133_b5-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20210812133133_b6-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20210812133133_b7-etm-0-0-10459","first-page":"109","article-title":"An updated review of rheumatic manifestations of malignancy and anti-neoplastic therapy","volume":"70","author":"Alias","year":"2012","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"key20210812133133_b8-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210812133133_b9-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29 (Suppl 4)","author":"Haanen","year":"2018","journal-title":"Ann Onco"},{"key":"key20210812133133_b10-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3904\/kjim.2019.060","article-title":"Rheumatic complications in cancer patients treated with immune checkpoint inhibitors","volume":"34","author":"Kyung-Ann","year":"2019","journal-title":"Korean J Intern Med"},{"key":"key20210812133133_b11-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfiield","year":"2005","journal-title":"J Immunother"},{"key":"key20210812133133_b12-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","article-title":"Checkpoint blocking antibodies in cancer immunotherapy","volume":"588","author":"Kyi","year":"2014","journal-title":"FERBS Lett"},{"key":"key20210812133133_b13-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"49","key":"key20210812133133_b14-etm-0-0-10459","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"key20210812133133_b15-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20210812133133_b16-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key20210812133133_b17-etm-0-0-10459","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28 (Suppl 4)","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"key20210812133133_b18-etm-0-0-10459","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/ijr.10.101","article-title":"Musculoskeletal ultrasound scoring systems: Assessing disease activity and therapeutic response in rheumatoid arthritis","volume":"6","author":"Ohrndorf","year":"2011","journal-title":"Int J Clin Rheumatol"},{"issue":"e000412","key":"key20210812133133_b19-etm-0-0-10459","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T10:32:28Z","timestamp":1628764348000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,7,16]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10459","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"article-number":"1027"}}